---
title: "Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293470001.md"
description: "Monopar Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for ALXN1840 to treat Wilson disease. The FDA has authorized this rolling review, with initial sections already submitted. Additionally, ALXN1840 received Rare Pediatric Disease designation in June 2026, making it eligible for a pediatric priority review voucher upon approval."
datetime: "2026-07-22T12:01:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293470001.md)
  - [en](https://longbridge.com/en/news/293470001.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293470001.md)
generator: "portal-rs"
---

# Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease

-   Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 in Wilson disease. \* The FDA authorized the rolling review; initial NDA sections have been submitted. \* ALXN1840 received FDA Rare Pediatric Disease designation in June 2026, supporting eligibility for a pediatric priority review voucher at approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220800PRIMZONEFULLFEED9765768) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MNPR.US](https://longbridge.com/en/quote/MNPR.US.md)

## Related News & Research

- [Monopar says FDA grants rare pediatric disease designation for ALXN1840 in Wilson disease](https://longbridge.com/en/news/291279018.md)
- [Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares](https://longbridge.com/en/news/297238555.md)
- [Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease](https://longbridge.com/en/news/297858517.md)
- [IONS: FDA approved ZANVASTRO for Alexander disease, enabling broad patient access and rapid launch](https://longbridge.com/en/news/298060316.md)
- [aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol](https://longbridge.com/en/news/297696098.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**